Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Key takeaways
- JNJ’s Q3 earnings are expected to dip slightly, but rising analyst targets and positive drug data may cushion the impact on the stock.
- EPS estimate: $2.48
- Revenue estimate: $25.31 billion
- Last year EPS: $2.80
What happened
Johnson & Johnson (NYSE: JNJ) is set to report its third‑quarter earnings on Oct. 13, with analysts forecasting earnings per share of $2.48 versus $2.80 a year ago and revenue of $25.31 billion versus $23.99 billion last year. On Sept. 25 the company announced positive clinical results for its therapies Tremfya (psoriatic arthritis) and Carvykti (multiple myeloma). Analyst ratings have been mixed but largely upbeat, with price targets raised from $270–$320 to $285–$320 across five major firms.
Why it matters
The earnings cut signals a modest decline in profitability, but the revenue growth and strong clinical data could offset concerns. Rising price targets suggest analysts expect the company to rebound, potentially supporting the stock’s recent 1.6% decline to $267.57. Investors are watching whether the clinical gains…
Short-term and longer-term
Short-term. Short‑term traders should monitor the Oct.
Longer-term. Over the next few months, investors should assess how the positive clinical data for Tremfya and Carvykti translate into sales growth and margin improvement.